SynthesisBMC cancer2026
Systematic review and meta-analysis of lung metastases incidence in cervical cancer patients.
Synthesis in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCervical cancer (CC) is a common and aggressive malignancy in women. The lung is its most frequent site of distant metastasis, yet the incidence and risk factors remain underexplored. This study aimed to estimate the incidence of lung metastases (LMs) in CC and characterize their clinical and pathological patterns.
methodsWe systematically searched PubMed/Medline, Scopus, Embase, Web of Science, and Google Scholar up to May 8, 2025, for studies reporting LMs incidence in CC patients. Eligible studies were assessed using the Joanna Briggs Institute (JBI) tool. Data were analyzed with STATA version 17 using a random-effects model. Pooled estimates were reported with 95% confidence intervals (CIs).
resultsThe global pooled incidence of LMs in CC was 4.31% (95% CI: 3.25-5.37), with the highest regional rate observed in Africa (7.42%). Neuroendocrine carcinoma (NEC) demonstrated the highest histology-specific LMs incidence at 16.91% (95% CI: 11.06-22.76), markedly exceeding adenocarcinoma and squamous cell carcinoma. LMs risk was substantially elevated in advanced stages, rising to 15.75% (95% CI: 4.92-26.58) in stage IV compared to 3.12% (95% CI: 1.74-4.51) in stage I, with an average post-metastasis survival of 32.56 months (95% CI: 7.57-57.54).
conclusionOur results show that the lung is a common site for metastasis in CC, often alongside liver and bone metastases. LMs risk is higher in neuroendocrine carcinoma and advanced stages. These findings can help improve prevention and treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.